Menu
Jonathan Tobin

About Jonathan

Jonathan joined Imperial Innovations in 2011 and specialises in therapeutics and diagnostics investments. He is a board director with antibacterial drug discovery company Auspherix, and diagnostics companies Abingdon Health and Molecular Vision, and a board observer with Cell Medica and Psioxus. Prior to joining Imperial Innovations he worked at MRC Technology, sourcing and evaluating new opportunities for small molecule and antibody drug discovery worldwide. He has a PhD in molecular medicine from UCL, and undertook post-doctoral research at the Cancer Research UK LRI. Jonathan has a First Class degree in Biology from Oxford University and an MBA with Distinction from Imperial College.

Contact

Email jonathan.tobin@imperialinnovations.co.uk

Companies

Therapeutics
Investment amount
£12.3m
Investment share
27.0%
Source
Imperial College London
Investment stage
post-Series A

Developing cell based products for immune reconstitution and ...

Find out more
Therapeutics
Investment amount
£9.5m
Investment share
28.5%
Source
University of Oxford
Investment stage
post-Series A

Innovative therapeutics for serious diseases with a particular ...

Find out more
Medtech
Investment amount
£5.8m
Investment share
35.5%
Source
Imperial College London
Investment stage
post-Series A

Developer and distributer of state-of-the-art diagnostic tools and ...

Find out more
Therapeutics
Investment share
27.5%
Source
Other

Novel anti-infectives to overcome antibiotic resistance

Find out more